Navigation Links
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013

ATLANTA, Nov. 15, 2013 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2). These findings, presented for the first time at Obesity Week 2013 on November 15, 2013, demonstrated significant weight loss and improvements in cardiometabolic risk markers in 147 obese individuals over 12 weeks of treatment, the largest and longest trial to date for the beloranib program.

"The latest results from this robust, larger scale trial represent the first full set of Phase 2 data for beloranib in severely obese patients," said Thomas Hughes, Ph.D., President and CEO of Zafgen.  "This patient population often remains beyond the reach of existing pharmacotherapy and there is a major unmet medical need for treatment of this serious disease.  We are very encouraged by the extent of weight loss observed in this trial and will continue to pursue beloranib as a pharmacological alternative to bariatric surgery."

Beloranib, a novel obesity therapy that utilizes a unique mechanism of action, is being studied for its ability to reduce body weight and improve cardiometabolic risk factors in obese patients.  The study presented was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a dose range of beloranib administered as twice-weekly subcutaneous injections for 12 weeks.  The trial enrolled 147 patients, of which 122 completed the study.  Subjects were mostly obese women with mean age 48.4 years, body weight (BW) 100.9  kg, and body mass index (BMI) 37.6 kg/m2, who were enrolled into one of the four arms of the trial (N=37 in 0.6 mg, 37 in 1.2 mg, 35 in 2.4 mg and 38 in placebo arm). Patients were allowed to eat normally and were not counseled to change their diet or exercise habits.

Results from this study showed that after 12 weeks of treatment, subjects on 0.6 mg, 1.2 mg, or 2.4 mg of beloranib lost on average (+/- standard error of mean) -5.5 +/- 0.5 kg, -6.9 +/- 0.6 kg, and -10.9 +/- 1.1 kg, respectively vs. -0.4 +/- 0.4 kg for those on placebo (all p<0.0001 vs. placebo).  The study also showed that weight loss with beloranib was progressive and continuing at week 12, reduced sense of hunger, improved cardiometabolic risk markers, and was generally well-tolerated.  In addition to confirming the findings from previous studies that showed improvements in LDL-cholesterol, HDL-cholesterol and triglycerides, this study also demonstrated beloranib's effects to lower blood pressure.  Using 24-hour Ambulatory Blood Pressure Monitoring, clinically and statistically significant improvements in systolic blood pressure were observed for the 1.2 mg and 2.4 mg doses, showing reductions of 7.6 mmHg and 12.0 mmHg, respectively.

There were no serious adverse events (AEs) deemed to be related to the study drug and no clinically significant abnormal laboratory measures, vital signs, or electrocardiography (ECG) findings.  The most common adverse events with a higher incidence rate in those taking beloranib vs. placebo were nausea, diarrhea, headache, injection site bruising, and insomnia.  These adverse events were generally mild, transient and self-limiting in nature.

"These full Phase 2 results are an exciting prospect for the treatment of severely obese patients," said Louis Aronne, M.D., Clinical Professor of Medicine at Weill Cornell Medical College.1 "Beloranib continues to demonstrate a unique ability to deliver rapid and significant weight loss as well as meaningful improvements in key cardiometabolic risk markers.  Based on this supporting data, beloranib has the potential to be a highly effective and promising treatment option for life-threatening, severe obesity."  

About Fat Metabolism
Research continues to show that obese and lean individuals metabolize fat differently.  Studies indicate that once a person becomes obese, the body undergoes certain metabolic changes and is "programmed" to make and store more fat, making it much more difficult to reduce body weight.  These metabolic adaptations that take place in obese people impair the normal release and breakdown of fatty acids from adipose tissue.  Simultaneously, the body becomes much more efficient in diverting calories from food and storing them as fat, making it difficult for obese patients to lose weight.

About Beloranib
Beloranib is the first compound in its class that works by targeting a key enzyme called methionine aminopeptidase 2 (MetAP2) that controls the production and utilization of fatty acids.  Inhibitors of MetAP2 reduce hunger while also reducing the production of new fatty acid molecules by the liver and helping to convert stored fats into useful energy.  Beloranib is being developed as a twice-weekly subcutaneous injection for severe obesity.  Zafgen holds exclusive worldwide rights (exclusive of Korea) for development and commercialization of beloranib.

About Zafgen, Inc.
Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients by bringing beloranib, a first-in-class novel medicine, to market.  Founded in 2005 as a virtual company, Zafgen brings together leading experts in obesity and metabolic disease to address the underserved and growing population of patients who are severely obese.  Zafgen's singular focus is on advancing novel therapeutics for patients suffering from severe obesity and obesity-related disorders.  The company is located in Cambridge, MA.  For more information, visit

Poster Number 05-LB-P

1 Dr. Aronne has been granted stock option grants from Zafgen and also serves on the Company's Clinical Advisory Board


SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
(Date:10/13/2015)... China Jo-Jo Drugstores, Inc. (NASDAQ ... a leading China-based retail, wholesale and online distributor of ... and retail pharmacies, announced preliminary half year fiscal 2016 ... through , growing 438% year over year, ... China Jo-Jo,s online sales are principally ...
(Date:10/13/2015)...  XiMo AG ( Lucerne , ... Milpitas, California ) announced today the launch ... importance of metathesis chemistry was highlighted by the Nobel ... application. This industrially-relevant application has been utilized in the ... chemicals, and polymers. Georg Fráter , COO ...
(Date:10/12/2015)... -- Apheresis is an invasive process that ... and other components from whole blood. In this procedure, the ... an apheresis machine or a blood cell separator. The apheresis ... other blood components. A selected part of the blood is ... or the patient. It involves the use of devices and ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... "My friend's son suffers from eczema, and ... cheeks," said an inventor from Platteville, Colo. "I came up with this kit as ... the UNTOUCHABLE to prevent a child from rubbing or scratching his or her face. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology ... innovative health programs and interventions via mobile devices that provide a framework for ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG ... Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and led ...
(Date:10/13/2015)... ... 2015 , ... In an age where the cost of energy is rising, ... foot than in 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 ... eight percent. , According to Facilities Management Administrative Director Dieter Reichmann, this is ...
(Date:10/13/2015)... ... 2015 , ... e-con Systems Inc., a leading embedded design services company specializing ... first RGB-IR pixel format camera with a USB 3.0 interface and e-CAM40_CUMI4682_MOD, ... UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a 4-megapixel image ...
Breaking Medicine News(10 mins):